CN117462558A - 反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备 - Google Patents

反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备 Download PDF

Info

Publication number
CN117462558A
CN117462558A CN202311350513.0A CN202311350513A CN117462558A CN 117462558 A CN117462558 A CN 117462558A CN 202311350513 A CN202311350513 A CN 202311350513A CN 117462558 A CN117462558 A CN 117462558A
Authority
CN
China
Prior art keywords
composition
iii
hind
present
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311350513.0A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·沃科维斯基
凯文·希尔
亚当·凯瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bode Therapeutics
Original Assignee
Bode Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bode Therapeutics filed Critical Bode Therapeutics
Publication of CN117462558A publication Critical patent/CN117462558A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202311350513.0A 2017-05-05 2018-05-07 反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备 Pending CN117462558A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762501984P 2017-05-05 2017-05-05
US62/501,984 2017-05-05
CN201880043453.9A CN111372939B (zh) 2017-05-05 2018-05-07 反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备
PCT/US2018/031436 WO2018204930A1 (en) 2017-05-05 2018-05-07 Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880043453.9A Division CN111372939B (zh) 2017-05-05 2018-05-07 反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备

Publications (1)

Publication Number Publication Date
CN117462558A true CN117462558A (zh) 2024-01-30

Family

ID=64016742

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311350513.0A Pending CN117462558A (zh) 2017-05-05 2018-05-07 反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备
CN201880043453.9A Active CN111372939B (zh) 2017-05-05 2018-05-07 反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880043453.9A Active CN111372939B (zh) 2017-05-05 2018-05-07 反式-[四氯双(1h-吲唑)钌(iii)]及其组合物的制备

Country Status (11)

Country Link
US (5) US10611787B2 (enExample)
EP (3) EP3618827B1 (enExample)
JP (4) JP7183253B2 (enExample)
CN (2) CN117462558A (enExample)
AU (2) AU2018263965B2 (enExample)
CA (1) CA3062369A1 (enExample)
ES (1) ES2959891T3 (enExample)
PL (1) PL3618827T3 (enExample)
RU (1) RU2019138773A (enExample)
SG (1) SG11201910043PA (enExample)
WO (1) WO2018204930A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
EP4247413A4 (en) * 2020-11-18 2024-10-09 Bold Therapeutics Inc. USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERS

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10103565A1 (de) * 2001-01-26 2002-08-14 Faustus Forschungs Cie Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
CN101677572A (zh) * 2007-06-11 2010-03-24 尼基制药公司 制备钌络合物的方法
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
US20130190285A1 (en) * 2009-12-11 2013-07-25 Niiki Pharma Inc. Method of treating pancreatic cancer
CN103601759A (zh) * 2013-10-18 2014-02-26 武汉利宝瑞医药科技有限公司 一种用于治疗肿瘤的钌（iii）络合物的制备方法
WO2016209918A1 (en) * 2015-06-23 2016-12-29 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612291A1 (de) * 1996-03-28 1997-10-02 Bernhard K Prof Dr Dr Keppler Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe
JP5826259B2 (ja) 2010-06-22 2015-12-02 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ ルテニウムベース錯体
US10766915B2 (en) 2013-03-15 2020-09-08 Sherri Ann McFARLAND Metal-based coordination complexes as photodynamic compounds and their use
EP3618827B1 (en) * 2017-05-05 2023-07-26 Bold Therapeutics Inc. Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10103565A1 (de) * 2001-01-26 2002-08-14 Faustus Forschungs Cie Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus
CN101677572A (zh) * 2007-06-11 2010-03-24 尼基制药公司 制备钌络合物的方法
US20130190285A1 (en) * 2009-12-11 2013-07-25 Niiki Pharma Inc. Method of treating pancreatic cancer
CN103153303A (zh) * 2010-07-18 2013-06-12 尼基制药公司 使用钌络合物的联合疗法
CN103601759A (zh) * 2013-10-18 2014-02-26 武汉利宝瑞医药科技有限公司 一种用于治疗肿瘤的钌（iii）络合物的制备方法
WO2016209918A1 (en) * 2015-06-23 2016-12-29 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王飞利, 柴晓华, 聂万利, 等: "抗癌钌配合物NAMI-A和ICR的合成、水解及其与DNA的相互作用", 《化学试剂》, vol. 31, no. 5, 17 June 2009 (2009-06-17), pages 324 - 326 *

Also Published As

Publication number Publication date
EP4245305A2 (en) 2023-09-20
EP3618827C0 (en) 2023-07-26
US20180327435A1 (en) 2018-11-15
EP4245305A3 (en) 2023-10-04
SG11201910043PA (en) 2019-11-28
EP3618827A4 (en) 2020-09-02
EP4245305C0 (en) 2025-10-08
RU2019138773A (ru) 2021-06-08
ES2959891T3 (es) 2024-02-28
AU2018263965A1 (en) 2019-11-21
JP7183253B2 (ja) 2022-12-05
JP7698083B2 (ja) 2025-06-24
US12415825B2 (en) 2025-09-16
WO2018204930A1 (en) 2018-11-08
US20200262855A1 (en) 2020-08-20
JP7433402B2 (ja) 2024-02-19
US20210277040A1 (en) 2021-09-09
EP4635503A2 (en) 2025-10-22
PL3618827T3 (pl) 2024-01-22
US11739111B2 (en) 2023-08-29
JP2023016867A (ja) 2023-02-02
US10611787B2 (en) 2020-04-07
JP2024045436A (ja) 2024-04-02
EP3618827A1 (en) 2020-03-11
EP4635503A3 (en) 2025-10-29
CN111372939A (zh) 2020-07-03
US20230357297A1 (en) 2023-11-09
CN111372939B (zh) 2023-11-07
US20260042792A1 (en) 2026-02-12
JP2020518676A (ja) 2020-06-25
CA3062369A1 (en) 2018-11-08
AU2018263965B2 (en) 2024-02-29
AU2024203511A1 (en) 2024-06-20
RU2019138773A3 (enExample) 2022-02-01
EP3618827B1 (en) 2023-07-26
AU2024203511B2 (en) 2026-03-19
JP2025123344A (ja) 2025-08-22
EP4245305B1 (en) 2025-10-08
US11040993B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
JP7698083B2 (ja) トランス－［テトラクロロビス（１ｈ－インダゾール）ルテニウム酸（ｉｉｉ）］及びその組成物の製造
US20130005696A1 (en) Bufadienolide derivatives, preparing process thereof, composition comprising the same and the use thereof
EP0300969A2 (de) Polyethylenglykolcarbaminate
KR102412203B1 (ko) 백금 내성을 극복하는데 이용하기 위한 텍사피린-pt(iv) 접합체 및 조성물
CN112930214A (zh) 含氘化合物
US20250213698A1 (en) Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents
EP4455131A1 (en) Aromatic vinyl compound, metal complex thereof, and preparation method therefor and use thereof
CN102653522B (zh) ω-羧基取代的二苯基硫脲类化合物及其制备方法和用途
EA019693B1 (ru) СПОСОБ ПОЛУЧЕНИЯ 2-[4-(4-ФТОР-2-МЕТИЛ-1H-ИНДОЛ-5-ИЛОКСИ)-5-МЕТИЛПИРРОЛО[2,1-f][1,2,4]ТРИАЗИН-6-ИЛОКСИ]-1-МЕТИЛЭТИЛОВОГО ЭФИРА [(1R),2S]-2-АМИНОПРОПИОНОВОЙ КИСЛОТЫ
JPH10502088A (ja) ブレフェルジンａの新しい誘導体およびがん治療におけるそれらの有用性
CN106083960B (zh) 新型紫杉类化合物及其制备方法和应用
CN110218230B (zh) 维生素c偶联铂配合物、其中间体、其制备方法、药物组合物及用途
TW202302591A (zh) 表伴護蛋白體(epichaperome)抑制劑之sn標記及放射性標記
HK40008502A (en) Vitamin c-platinum complex and intermediary, preparation method, pharmaceutical composition and use thereof
HK40008502B (en) Vitamin c-platinum complex and intermediary, preparation method, pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination